DP
Therapeutic Areas
Sermonix Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lasofoxifene (ELAINE Program) | Locally advanced or metastatic ER+/HER2- breast cancer with ESR1 mutation | Phase 2 |
| Lasofoxifene + Abemaciclib (ELAINE-2) | Locally advanced or metastatic ER+/HER2- breast cancer with ESR1 mutation | Phase 2 |